Tomasz Milczek

Summary

Publications

  1. doi request reprint Regimens with intraperitoneal cisplatin plus intravenuous cyclophosphamide and intraperitoneal carboplatin plus intravenuous cyclophosphamide are equally effective in second line intraperitoneal chemotherapy for advanced ovarian cancer
    T Milczek
    Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdansk, Poland
    Adv Med Sci 57:46-50. 2012
  2. doi request reprint Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer
    Tomasz Milczek
    Department of Gynecology and Gynecologic Oncology, Medical University of Gdansk, Poland
    Acta Obstet Gynecol Scand 88:463-7. 2009
  3. ncbi request reprint Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma
    Ewa Joanna Majdak
    Department of Gynecology, Medical University of Gdansk, Poland
    Cancer 104:1004-12. 2005
  4. pmc Prognostic factors and a value of 2009 FIGO staging system in vulvar cancer
    Jacek J Sznurkowski
    Department of Oncological Surgery, Medical University of Gdansk, Gdansk, Poland
    Arch Gynecol Obstet 287:1211-8. 2013
  5. doi request reprint Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients
    Dagmara Klasa-Mazurkiewicz
    Department of Gynecology Oncology, Medical University of Gdansk, Kliniczna, 1a, 80 402 Gdansk, Poland
    Gynecol Oncol 113:91-8. 2009
  6. ncbi request reprint Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report
    Ewa J Majdak
    Department of Gynecology, Medical University of Gdansk, ul Kliniczna 1A, Gdnask, Poland
    Eur J Cancer 41:143-50. 2005

Collaborators

Detail Information

Publications6

  1. doi request reprint Regimens with intraperitoneal cisplatin plus intravenuous cyclophosphamide and intraperitoneal carboplatin plus intravenuous cyclophosphamide are equally effective in second line intraperitoneal chemotherapy for advanced ovarian cancer
    T Milczek
    Department of Gynaecology, Gynaecological Oncology and Gynaecological Endocrinology, Medical University of Gdansk, Poland
    Adv Med Sci 57:46-50. 2012
    ....
  2. doi request reprint Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer
    Tomasz Milczek
    Department of Gynecology and Gynecologic Oncology, Medical University of Gdansk, Poland
    Acta Obstet Gynecol Scand 88:463-7. 2009
    ..To report the results of ovarian cancer treatment, where a regimen of intravenous cyclophosphamide followed by intraperitoneal cisplatin or carboplatin was administered as second line treatment...
  3. ncbi request reprint Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma
    Ewa Joanna Majdak
    Department of Gynecology, Medical University of Gdansk, Poland
    Cancer 104:1004-12. 2005
    ..Our aim was to determine factors influencing the risk of recurrence and death in ovarian carcinoma patients with BRCA pathogenic and unclassified variant mutations...
  4. pmc Prognostic factors and a value of 2009 FIGO staging system in vulvar cancer
    Jacek J Sznurkowski
    Department of Oncological Surgery, Medical University of Gdansk, Gdansk, Poland
    Arch Gynecol Obstet 287:1211-8. 2013
    ..The aim of this study was to test prognostic ability of 2009 staging in a cohort of uniformly treated and staged cases with long-term follow-up...
  5. doi request reprint Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients
    Dagmara Klasa-Mazurkiewicz
    Department of Gynecology Oncology, Medical University of Gdansk, Kliniczna, 1a, 80 402 Gdansk, Poland
    Gynecol Oncol 113:91-8. 2009
    ..We examined maspin expression in human ovarian tumors and relation between maspin expression and clinicopathological features as well as the role of maspin in predicting clinical outcome in patients with ovarian cancer...
  6. ncbi request reprint Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report
    Ewa J Majdak
    Department of Gynecology, Medical University of Gdansk, ul Kliniczna 1A, Gdnask, Poland
    Eur J Cancer 41:143-50. 2005
    ..Except for infertility and hyperthyroidism, unclassified variant-linked ovarian tumours share features with sporadic tumours rather than with BRCA1 pathogenic mutations...